In-depth guides
Plain-language guides identify the terms commonly used around iboga root bark and ibogaine, then separate cultural context, plant material, chemistry, and claims that require caution.
Information services
Services
Clear, safety-conscious guides and comparison tools for understanding iboga root bark, ibogaine, and the meaningful differences between plant material and purified products.
Independent context, plain language, and careful attention to uncertainty and serious safety concerns.
These are information services—not medical or clinical services. They are designed for people seeking a careful starting point: what a term refers to, what it does not establish, and where evidence and safety questions remain. The broader iboga root bark overview introduces the same subject with an emphasis on distinctions rather than assumptions.
Ways to use this resource
01
02
03
04
Practical context without clinical promises
Comparison frameworks
Side-by-side explanations help distinguish root bark from purified ibogaine products, including why a raw botanical material can have variable composition and why labels alone do not answer safety questions.
Research summaries
Research summaries place studies in context, noting what was examined, what remains uncertain, and why the U.S. Food and Drug Administration’s drug development process is distinct from general discussion of a substance.
Glossary and FAQ collections
Short definitions and recurring questions make terminology easier to follow. Our approach and editorial principles explain the limits of this independent resource and the care taken around uncertain evidence.
Root bark is not a synonym for purified ibogaine
Iboga is commonly associated with Tabernanthe iboga, a plant whose root bark may contain ibogaine among other alkaloids. A reference to root bark therefore describes plant material, not a standardized purified compound.
The difference is important because composition can vary by source, preparation, and other factors. This resource does not treat those distinctions as a measure of safety, quality, legality, or suitability. For treatment-oriented context found elsewhere online, ibogaine treatment for addiction is a separate topic from the informational comparisons presented here.
Questions worth keeping in view
A careful reading process does not turn information into individualized advice. It can, however, make it easier to notice when language is too broad, when a source is making a claim beyond its evidence, or when an important risk has been left out.
Evidence awareness includes limits and harm information
Ibogaine has been associated with serious cardiac risks. The National Library of Medicine’s LiverTox overview notes reported severe adverse events and underscores why broad online claims should not be mistaken for a safety assessment.
“Clear terminology is not a substitute for caution—but it is a necessary place to start.”
Common questions
Useful boundaries for this information
Are these medical or treatment services?
No. Clear Almanac 13 provides independent informational material only. It does not offer treatment, diagnosis, medical advice, or legal advice.
Why distinguish root bark from purified ibogaine?
A plant material can contain multiple constituents and variable alkaloid content, while a purified compound describes something different. The distinction matters when considering evidence, terminology, risk, and regulation.
What do research summaries aim to do?
They aim to identify the scope and limits of a source in plain language. A summary is not an endorsement, and it cannot determine whether a substance is appropriate for any individual.
Context before conclusions
Our focus is an independent, evidence-aware understanding of iboga root bark, chemical variability, and differences from purified ibogaine products—while keeping cultural respect and serious safety concerns in view.